Tongshu Gene

Tongshu Gene, also known as Changzhou Tongshu Biotechnology Co., Ltd., is a high-tech biotechnology company founded in 2016 and headquartered in Shanghai, China. The company specializes in innovative cancer research and genetic technologies, with a primary focus on the research, development, production, and sales of gene testing products for cancer diagnosis.

Tongshu Gene has established itself as a leader in the field of tumor innovation, particularly in Next Generation Sequencing (NGS) library construction. The company has developed a systematic compliance operating system centered around high-throughput sequencing, with their NGS genetic testing services obtaining certifications for reagents, instruments, and bioinformatics software from China's National Medical Products Administration (NMPA).

The company's expertise extends to translational research, leveraging tumor evolution theory and genomics. They offer comprehensive services ranging from study design and genetic testing to data analysis and scientific paper writing support. Tongshu Gene's innovative approaches have earned them recognition in the industry, including awards for their NGS library construction techniques and high-sensitivity MSI testing technology.

Tongshu Gene has successfully secured significant funding, including a Series C financing round of 500 million yuan in 2021. This funding has been directed towards the clinical development of new In-vitro diagnosis (IVD) products, such as ctDNA and early tumor screening tools, as well as expanding their direct sales channels to major hospitals across China.

The company's mission revolves around innovation and creating value for cancer patients by providing practical and reliable genetic consulting services to both patients and healthcare professionals. Their work spans various aspects of cancer genomics, from basic research to clinical applications, positioning them as a key player in advancing precision medicine in oncology.